Hoosier Cancer Research Network (HCRN) is set to participate in the American Society of Clinical Oncology® (ASCO) 2025 Annual Meeting in Chicago from May 30 to June 3. During the event, four HCRN studies will be presented, working group meetings will take place, and HCRN will host a joint reception with the Big Ten Cancer Research Consortium. The HCRN team will also be present in the exhibit hall at booth # 36117.
Study Presentations
Four Hoosier Cancer Research Network studies, HCRN-GI23-643, HCRN-LUN21-534, HCRN-GU23-626, and HCRN-HN23-623 will be presented during ASCO.
HCRN-GI23-643: Combining low-dose regorafenib with pembrolizumab for patients with MSI-H colorectal cancer: REGPEM-CRC-01.
- Authors: Ibrahim Halil Sahin, Ronan Hsieh, Vikram Gorantla, Stacey Cohen, John Rhee, Rachael Safyan, Curtis Tatsuoka, E. Gabriela Chiorean, Mohamedtaki Tejani, Al Benson III, Patrick Boland, Richard Kim, Anwaar Saeed
- Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
- Poster Bd #: M21
- Abstract: https://meetings.asco.org/abstracts-presentations/241991
HCRN-LUN21-534: Delayed or upfront brain radiotherapy in treatment-naïve lung cancer patients with asymptomatic or minimally symptomatic brain metastases and ALK rearrangements (DURABLE)
- Authors: Joshua Palmer, Nathaniel Myall, Erin Schenk, Fawzi Abu Rous, Lai Wei, Carly Pilcher, Brian Spahnie, Charles Tobin, Kimberly Cameron, Dwight Owen
- Poster Session: Central Nervous System Tumors
- Poster Bd #: 135a
- Abstract: https://meetings.asco.org/abstracts-presentations/252230
HCRN-GU23-626: A phase II study of niraparib (N), abiraterone acetate (AA) plus prednisone (P) for Hispanic/Latino (HL) and non-Hispanic Black (NHB) patients with metastatic hormone sensitive prostate cancer (mHSPC) and deleterious homologous recombination repair alterations (HRRa; HARMONY)
- Authors: Qian Qin, Changchuan Jiang, Song Zhang, Suzanne Cole, Kevin Courtney, Jue Wang, Waddah Arafat, Joseph Vento, Karine Tawagi, Natalie Reizine, Marijo Bilusic, Molly McGuire, Amy Rowell, David Wise, Melissa Reimers, Elisabeth Heath, Tian Zhang
- Poster Session: Genitourinary Cancer – Prostate, Testicular, and Penile
- Poster Bd #: 319a
- Abstract: https://meetings.asco.org/abstracts-presentations/252387
HCRN-HN23-623: Neoadjuvant SBRT followed by evorpacept and pembrolizumab in HPV-mediated head and neck squamous cell carcinoma: Investigation of pathologic response
- Authors: Joseph Califano III, Andrew Sharabi, Ezra Cohen, Robert Saddawi-Konefka, Liza Blumenfeld, Karen Messer, Xinlian Zhang, Marka Crittenden, Brian Piening, Rom Leidner, Kristina Young, Steven Seung, Thomas Duhen, Timur Mitin, Kyaw Thein, Ryan Li, Richard Bell
- Publication-Only: Head and Neck Cancer
- Abstract: https://meetings.asco.org/abstracts-presentations/251316
Working Group Meetings
HCRN will host in-person meetings for the Breast Cancer, Gastrointestinal, Genitourinary, Thoracic, Sarcoma, Neuro-Oncology, Lymphoma, Myeloid, Correlative Sciences, and Melanoma Clinical Trial Working groups during ASCO 2025. For more information or to schedule time to meet with HCRN, please reach out to Randy Dillinger at rdillinger@hoosiercancer.org.
Reception
HCRN is hosting a combined reception for members of both HCRN and the Big Ten Cancer Research Consortium on Saturday, June 1 from 6:30 – 8:00 pm CT. This gathering will take place at voco Chicago Downtown 350 W. Wolf Point Plaza, in the LaSalle Room. This event is for member investigators and our network of institutions. For more information, please contact Suzanne Tansel at stansel@hoosiercancer.org.
About Hoosier Cancer Research Network:
Hoosier Cancer Research Network conducts innovative cancer clinical trials in collaboration with more than 100 academic and community clinical research sites across the United States. Our studies are designed by cancer researchers from our member institutions. The HCRN staff includes 55 team members who work together to support all aspects of the studies we manage, from the time we receive the initial concept from a researcher through the final publication of the study results. Currently, we are supporting more than 70 clinical trials across a wide range of cancer types. Over our 40-year history, more than 10,000 participants have enrolled in our clinical trials, leading to important discoveries that help cancer patients live longer and better after their cancer diagnosis.
